Job Offer: Molecular and Cellular Biology Engineer — Pancreatic Cancer

Il y a 23 heures

Marseille, Provence-Alpes-Côte d'Azur, France Crcm Marseille Temps plein

Missions:

The successful candidate will assist postdoctoral fellows and doctoral students with research projects focusing on the tumor microenvironment in pancreatic cancer.

Main activities:

Cell culture, plasmid cloning, plasmid design, confocal microscopy, protein biochemistry, Western blot, and protein purification. Literature review.

Side activities:

Analysis of glycosylation patterns using a glycoproteomic approach.

Knowledge:

Theoretical knowledge of cellular and molecular biology. Good knowledge of laboratory techniques for mammalian cells.

Skills:

Proficiency in molecular biology software, sequence alignment tools, and AlphaFold; experimental rigor. Ability to clearly present one’s work and reasoning.

Competences:

Be organized, available, enthusiastic, and reliable. Be able to communicate effectively, make suggestions, and summarize information. Enjoy working as part of a team and interacting with researchers, and be able to understand and articulate their needs. English (reading, speaking, writing).

Desired experience:

Laboratory experience in molecular biology. Desired degree: 5 years of post-secondary education.

Contract:

12-month fixed-term contract. Desired start date: November 1, 2026. Compensation based on qualifications.

Host organization:

The engineer will work within the Glynthera team , a leader in the study of the GALA pathway and O-glycosylation in solid tumors. The laboratory is dedicated to understanding the mechanisms by which changes in the glycosylation profiles of surface and secreted proteins promote tumor growth and survival, with a particular focus on pancreatic and liver cancers. Glynthera is part of the CRCM (UMR 1068), an international cancer research center affiliated with the CNRS, INSERM, Aix-Marseille University, and the Paoli-Calmettes Institute, located in southeastern France. The CRCM combines access to clinicians and patient samples, state-of-the‑art technological platforms, and an international pool of top‑tier scientists.

#J-18808-Ljbffr